Skip to main content
. 2020 Jul 22;46(4):1514–1524. doi: 10.3892/ijmm.2020.4681

Figure 1.

Figure 1

miR-135b-5pagomirenhancesthe anti-proliferation effect oftrastuzumab in HER-2 positive breast cancer cells. (A) The levels of miR-135b-5p in BT-474, SK-BR-3 and MCF-10A cells were evaluated using RT-qPCR. **P<0.01 vs. MCF-10A. (B) The cells were transfected with either agomir or NC for 48 h. The levels of miR-135b-5p in BT-474 and SK-BR-3 cells after transfection was detected using RT-qPCR. **P<0.01 vs. blank. Breast cancer cells (C) BT-474 and (D) SK-BR-3 were treated with trastuzumab (0, 0.5, 1, 2 or 4 µg/ml) and miR-135b-5p agomirfor 48 h. Cell viability was detected using a Cell-Counting Kit 8 assay. *P<0.05 and **P<0.01 vs. blank. miR, microRNA; RT-qPCR, reverse transcription-quantitative PCR; NC, negative control; OD, optical density.